Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Peters S., Angevin E., Alonso-Gordoa T., Rohrberg K., Melero I., Mellado B., Perez-Gracia J-L., Tabernero J., Adessi C., Boetsch C., Watson C., Dal Porto J., Dejardin D., Del Nagro C., Nicolini V., Evers S., Klein C., Leutgeb B., Pisa P., Rossmann E., Saro J., Umana P., Charo J., Teichgräber V., Steeghs N.
<p>Supplementary Figure S2. Percent reduction in B cell numbers and B cell/T cell ratios in human CD20 transgenic mice treated with obinutuzumab or rituximab in A, Spleen and B, Lymph nodes. C, Reduction in splenic marginal zone B cells in human CD20 transgenic mice treated with obinutuzumab or rituximab (n = 2 per group).</p>